1. Anderson MS, Gilmartin J, Mitselos A, Laethem T, van Bortel L, Kraft WK, Guo Y, Dockendorf MF, Wagner JA, Butterton J. Effect of ritonavir (RTV) and Tenofovir (TDF) on the pharmacokinetics of MK-1439, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV-1 infection. Presented at the Interscience Conference on Antimicrobial Agents & Chemotherapy – 53rd Annual. Denver, CO, 2013; H-1462.
2. Anderson MS, Gilmartin J, Cilissen C, De Lepeleire I, van Bortel L, Dockendorf MF, Tetteh E, Ancona JK, Liu R, Guo Y, Wagner JA, Butterton JR. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. Antivir Ther. 2015a;20(4):397–405.
3. Anderson MS, Khalilieh S, Yee KL, Liu R, Rizk ML, Shah V, Hussaini A, Song I, Ross L, Butterton JR, Fan L. A 2-Way Steady State PK Interaction Study of Doravirine (MK-1439) and Dolutegravir. Presented at the International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy – 16th Annual. Denver, CO, 2015b; p. 59.
4. Anderson MS, Chung C, Tetteh E, Yee KL, Guo Y, Rasmussen S, Wagner JA, Butterton JR, Fan L. Effect of ketoconazole on the pharmacokinetics of doravirine (MK-1439), a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection. Presented at the International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy – 16th Annual. Denver, CO, 2015c; p. 58.
5. Baba M, De Clercq E, Tanaka H, et al. Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives. Mol Pharmacol. 1991;39:805–10.